Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial

Bibliographic Details
Title:	Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial
Authors:	Bringhen, Sara, D'Agostino, Mattia ^, Giuliani, Nicola, Attucci, Irene ^, Zambello, Renato ^, Ronconi, Sonia ^, Vincelli, Iolanda Donatella ^, Allegra, Alessandro ^, Leonardi, Giovanna ^, Rossi, Giuseppe, Cattel, Francesco ^, Capra, Andrea ^, Galieni, Piero ^, Lombardo, Alessandra ^, Bonello, Francesca ^, Tosi, Patrizia ^, Cavalli, Maide Maria ^, Sciorsi, Elisa ^, Mannina, Donato ^, Ria, Roberto ^, Patriarca, Francesca ^, Cavo, Michele ^, Mangiacavalli, Silvia ^, Benevolo, Giulia ^, Evangelista, Andrea ^, Boccadoro, Mario, Bruno, Benedetto ^*, Larocca, Alessandra
Source:	In Blood 15 November 2022 140 Supplement 1:1814-1816
Database:	ScienceDirect